GRAL
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
GRAIL Inc.
- Nom
- GRAIL Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $5.9B
- Employés
- 910
- PDG
- Joshua J. Ofman
- Site web
- http://www.grail.com
- Marché
- BLLNBNRCSTLFLGTGHMYGN
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 81 452 titres (~8 335 303,67 $ US)
- Insiders
- Ofman Joshua J.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$7,149,680
Avg sell (VWAP, 90d window) $125.37 vs last close $139.91 (+11.6%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$2,539,566 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-15
- Liquidity
- Liquid $137,344,030/day · 20d vol
- Last synced
-
2026-10-26 21:10:30
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Ofman Joshua J. | Sell · S · 10b5-1 | 2,114 | $138.79 | $293,394 | Form 4 |
| 2026-10-05 | Freidin Aaron | Sell · S | 23,619 | $146.39 | $3,457,585 | Form 4 |
| 2026-10-05 | Partridge Andrew John | Sell · S | 7,873 | $146.39 | $1,152,528 | Form 4 |
| 2026-09-21 | Freidin Aaron | Sell · S · 10b5-1 | 521 | $95.00 | $49,495 | Form 4 |
| 2026-09-21 | Ofman Joshua J. | Sell · S · 10b5-1 | 10,000 | $110.00 | $1,100,000 | Form 4 |
| 2026-08-27 | Freidin Aaron | Sell · S · 10b5-1 | 7,900 | $85.01 | $671,579 | Form 4 |
| 2026-08-27 | Ofman Joshua J. | Sell · S · 10b5-1 | 5,000 | $85.02 | $425,098 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
GRAL combines a critically weak fundamental profile (persistent operating losses, zero interest coverage, no path to profitability) with a strongly negative catalyst signal driven by heavy CEO insider selling of $8.3M…
The first sentence of the analysis written for GRAL on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 11.97 · operating margin -363% — readings disagree
Suggested stop 122.76, nearest stored support minus 0.5 ATR(12.3% under the last close). Reward/risk to the next stored resistance is 0.31. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-18 GRAIL (NASDAQ:GRAL) Stock: Insider Joshua Ofman Sells 20,000 Shares GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Joshua Ofman sold 20,000 shares of the firm''s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $136.85, for a total value of $2,737,000.00. Following the transaction, the chief executive officer owned 342,271 shares in the company, valued at
- 2026-10-18 GRAIL (NASDAQ:GRAL) Stock Price Down 5.6% on Insider Selling GRAIL, Inc. (NASDAQ: GRAL - Get Free Report)''s stock price dropped 5.6% on Friday after an insider sold shares in the company. The stock traded as low as $129.03 and last traded at $127.9350. 67,481 shares traded hands during trading, a decline of 93% from the average session volume of 971,234 shares. The stock had previously
- 2026-10-12 11 Stocks Most Likely to See a Short Squeeze Rally Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
- 2026-10-12 First-Class Amenity Kits Have Become Holy Grail Collectibles For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They''re a trip down memory lane.
- 2026-10-11 Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here''s the Risk Investors Shouldn''t Ignore. Grail''s stock surged after a positive FDA panel vote. Insurer adoption is crucial for Galleri''s success.
- 2026-10-11 Head to Head Contrast: Gilead Sciences (NASDAQ:GILD) vs. GRAIL (NASDAQ:GRAL) Gilead Sciences (NASDAQ: GILD - Get Free Report) and GRAIL (NASDAQ: GRAL - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Gilead Sciences and
- 2026-10-08 2 Growth Stocks to Buy in October Grail and Veeva Systems could be well insulated from near-term headwinds.
- 2026-10-07 Why CVS Is ‘Insanely Cheap,'' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into their prices, and figuring out which side each sits on changes everything about whether to buy.
- 2026-10-05 GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to Present Two Abstracts at the European Society for Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence SUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the Early Detection of Cancer Conference (EDCC) in Edinburgh, the United Kingdom, taking place Oct. 6-8, 2026, and at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain taking place Oct. 23-27, 2026.
- 2026-10-04 Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years? Adoption by insurers and FDA approval are critical for future performance. Profitability is not expected until 2032/2033, but revenue growth could be strong if adoption accelerates.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -42.5% | -62.1% | -102.7% | -209.6% | -684.4% | |
| Ebit Margin | -363.2% | -611.7% | -855.9% | -1336.6% | -8659.0% | |
| Ebitda Margin | -257.0% | -485.8% | -685.5% | -1058.0% | -8259.0% | |
| Operating Profit Margin | -363.0% | -1743.0% | -1627.6% | -9798.2% | -8659.6% | |
| Pretax Profit Margin | -363.2% | -1721.7% | -1619.3% | -9795.5% | -8659.0% | |
| Continuous Operations Profit Margin | -277.5% | -1613.9% | -1574.2% | -9719.3% | -8539.4% | |
| Net Profit Margin | -277.5% | -1613.9% | -1574.2% | -9719.3% | -8539.4% | |
| Bottom Line Profit Margin | -277.5% | -1613.9% | -1574.2% | -9719.3% | -8539.4% | |
| Current Ratio | 11.972 | 10.658 | 0.954 | 2.191 | 2.480 | |
| Quick Ratio | 11.771 | 10.416 | 0.821 | 2.044 | 2.480 | |
| Solvency Ratio | -0.732 | -3.894 | -1.435 | -5.486 | -3.869 | |
| Cash Ratio | 3.135 | 2.785 | 0.595 | 1.790 | 2.259 | |
| Price To Earnings Ratio | -7.704 | -0.281 | -0.289 | -0.079 | -0.340 | |
| Price To Earnings Growth Ratio | 0.093 | -0.008 | 0.004 | -0.000 | -0.000 | |
| Forward Price To Earnings Growth Ratio | 0.093 | -0.008 | 0.004 | -0.000 | -0.000 | |
| Price To Earnings Diluted Ratio | -7.704 | -0.281 | -0.289 | -0.079 | -0.340 | |
| Price To Earnings Diluted Growth Ratio | 0.093 | -0.008 | 0.004 | -0.000 | -0.000 | |
| Price To Book Ratio | 1.220 | 0.227 | 0.116 | 0.091 | 0.045 | |
| Price To Sales Ratio | 21.375 | 4.534 | 4.556 | 7.636 | 29.029 | |
| Price To Free Cash Flow Ratio | -10.521 | -0.978 | -0.697 | -0.726 | -0.560 | |
| Price To Operating Cash Flow Ratio | -10.521 | -0.987 | -0.712 | -0.756 | -0.616 | |
| Debt To Assets Ratio | 0.034 | 0.023 | 0.019 | 0.017 | 0.011 | |
| Debt To Equity Ratio | 0.038 | 0.027 | 0.023 | 0.021 | 0.012 | |
| Debt To Capital Ratio | 0.037 | 0.026 | 0.023 | 0.020 | 0.012 | |
| Long Term Debt To Capital Ratio | 0.016 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.134 | 1.192 | 1.250 | 1.206 | 1.033 | |
| Working Capital Turnover Ratio | 0.182 | 0.342 | 1.216 | 0.364 | 0.044 | |
| Operating Cash Flow Ratio | -3.753 | -7.503 | -3.642 | -4.160 | -7.030 | |
| Operating Cash Flow Sales Ratio | -2.032 | -4.595 | -6.399 | -10.105 | -47.093 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.009 | 1.022 | 1.041 | 1.102 | |
| Debt Service Coverage Ratio | -21.511 | 0.000 | -40.264 | -40.900 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -25.523 | 0.000 | -40.232 | -42.093 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -3.051 | -8.470 | -7.059 | -5.846 | -6.224 | |
| Capital Expenditure Coverage Ratio | -328.941 | -110.821 | -46.233 | -24.555 | -9.841 | |
| Dividend Paid And Capex Coverage Ratio | -328.941 | -110.821 | -46.233 | -24.555 | -9.841 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.917 | -0.694 | -0.644 | -0.474 | -0.260 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -42.5% | ▲19.6% | ▲177.8% |
| Ebit Margin | -363.2% | ▲248.5% | ▲2002.1% |
| Ebitda Margin | -256.9% | ▲228.9% | ▲1892.1% |
| Operating Profit Margin | -363.0% | ▲1380.1% | ▲4075.3% |
| Pretax Profit Margin | -363.2% | ▲1358.5% | ▲4068.5% |
| Continuous Operations Profit Margin | -277.5% | ▲1336.5% | ▲4067.4% |
| Net Profit Margin | -277.5% | ▲1336.5% | ▲4067.4% |
| Bottom Line Profit Margin | -277.5% | ▲1336.5% | ▲4067.4% |
| Current Ratio | 11.973 | ▲1.315 | ▲6.322 |
| Quick Ratio | 11.771 | ▲1.356 | ▲6.265 |
| Solvency Ratio | -0.732 | ▲3.162 | ▲2.351 |
| Cash Ratio | 3.135 | ▲0.349 | ▲1.022 |
| Price To Earnings Ratio | -7.704 | ▼-7.423 | ▼-5.965 |
| Price To Earnings Growth Ratio | 0.093 | ▲0.102 | ▲0.076 |
| Forward Price To Earnings Growth Ratio | 0.093 | ▲0.102 | ▲0.076 |
| Price To Earnings Diluted Ratio | -7.704 | ▼-7.423 | ▼-5.965 |
| Price To Earnings Diluted Growth Ratio | 0.093 | ▲0.102 | ▲0.076 |
| Price To Book Ratio | 1.220 | ▲0.993 | ▲0.880 |
| Price To Sales Ratio | 21.375 | ▲16.841 | ▲7.949 |
| Price To Free Cash Flow Ratio | -10.521 | ▼-9.543 | ▼-7.824 |
| Price To Operating Cash Flow Ratio | -10.521 | ▼-9.534 | ▼-7.802 |
| Debt To Assets Ratio | 0.034 | ▲0.011 | ▲0.013 |
| Debt To Equity Ratio | 0.038 | ▲0.011 | ▲0.014 |
| Debt To Capital Ratio | 0.037 | ▲0.010 | ▲0.013 |
| Long Term Debt To Capital Ratio | 0.017 | ▲0.017 | ▲0.013 |
| Financial Leverage Ratio | 1.133 | ▼-0.058 | ▼-0.029 |
| Working Capital Turnover Ratio | 0.182 | ▼-0.160 | ▼-0.247 |
| Operating Cash Flow Ratio | -3.753 | ▲3.750 | ▲1.464 |
| Operating Cash Flow Sales Ratio | -2.032 | ▲2.564 | ▲12.013 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.009 | ▼-0.035 |
| Debt Service Coverage Ratio | -21.512 | ▼-21.512 | ▼-0.976 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -25.523 | ▼-25.523 | ▼-3.954 |
| Operating Cash Flow Coverage Ratio | -3.051 | ▲5.419 | ▲3.079 |
| Capital Expenditure Coverage Ratio | -328.941 | ▼-218.119 | ▼-224.863 |
| Dividend Paid And Capex Coverage Ratio | -328.941 | ▼-218.119 | ▼-224.863 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.917 | ▼-7.224 | ▼-5.920 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.15B | $569.4M | $424.2M | $424.2M | $424.2M | |
| Enterprise value | $2.99B | $423.3M | $411.3M | $278.6M | $313.6M | |
| EV / Sales | 20.34x | 3.37x | 4.42x | 5.01x | 21.46x | |
| EV / Op. cash flow | -10.01x | -0.73x | -0.69x | -0.50x | -0.46x | |
| EV / Free cash flow | -10.01x | -0.73x | -0.68x | -0.48x | -0.41x | |
| EV / EBITDA | -7.92x | -0.69x | -0.64x | -0.47x | -0.26x | |
| Net debt / EBITDA | 0.40x | 0.24x | 0.02x | 0.25x | 0.09x | |
| Current ratio | 11.97x | 10.66x | 0.95x | 2.19x | 2.48x | |
| Income quality | 0.73x | 0.28x | 0.41x | 0.10x | 0.55x | |
| Graham net-net | $16 | $10 | -$25 | -$22 | -$3 | |
| Tax burden | 76.4% | 93.7% | 97.2% | 99.2% | 98.6% | |
| Interest burden | 100.0% | 281.5% | 189.2% | 732.9% | 100.0% | |
| Working capital | $874.2M | $742.9M | -$7.5M | $160.7M | $144.8M | |
| Invested capital | $2.83B | $2.90B | $3.74B | $4.79B | $9.63B | |
| Return on assets | -14.0% | -67.9% | -32.2% | -96.4% | -12.8% | |
| Operating ROA | -18.1% | -58.1% | -29.8% | -71.0% | -24.2% | |
| Return on tangible assets | -38.1% | -209.7% | -149.4% | -461.8% | -267.6% | |
| Return on equity | -15.8% | -81.0% | -40.2% | -116.2% | -13.2% | |
| Return on invested capital | -14.3% | -70.3% | -33.4% | -98.5% | -12.9% | |
| Return on capital employed | -18.8% | -75.3% | -34.5% | -99.6% | -13.1% | |
| Earnings yield | -13.0% | -356.0% | -345.5% | -1272.8% | -294.2% | |
| Free cash flow yield | -9.5% | -102.3% | -143.5% | -137.7% | -178.7% | |
| Capex / Op. cash flow | -0.3% | -0.9% | -2.2% | -4.1% | -10.2% | |
| Capex / Depreciation | 0.6% | 3.3% | 8.1% | 14.8% | 119.6% | |
| Capex / Sales | 0.6% | 4.1% | 13.8% | 41.2% | 478.6% | |
| SG&A / Sales | 187.4% | 292.9% | 389.4% | 533.6% | 1601.8% | |
| R&D / Sales | 133.0% | 256.7% | 363.8% | 593.3% | 3149.5% | |
| Stock comp / Sales | 39.6% | 68.5% | 104.4% | 136.3% | 4666.8% | |
| Intangibles / Total assets | 63.3% | 67.6% | 78.5% | 79.1% | 95.2% | |
| Days sales outstanding | 45d | 72d | 88d | 122d | 172d | |
| Days payables outstanding | 4d | 9d | 38d | 37d | 56d | |
| Operating cycle | 73d | 105d | 130d | 164d | 172d | |
| Cash conversion cycle | 70d | 96d | 92d | 127d | 116d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years